An Muhsin

About An Muhsin

20+ years of drug development and medical practice. Experience with a wide array of solid tumors across the tumor immunogenicity spectrum, from tumors as hot/immunogenic as melanoma to tumors as cold as pancreatic ductal adenocarcinoma and almost all tumors in between, including NSCLC (squamous/non-squamous), gasrtic/GEJ, cholangiocarcinoma and hepatobiliary, TNBC, SCCHN. Merkel, CSCC and others in IV, SQ and IT drug delivery routes of administration. Leverages deep medical expertise as a global thought leader in immuno-oncology, tumor microenvironment (TME), novel adaptive trial designs. Designed and led flawless execution of phase clinical trials with CPIs, TLRs, HDACi, Gene Therapies, Targeted Therapies, Cytokines/Chemokines, and other TME modifiers and drug classes. In-depth knowledge of the oncology landscape and its evolving therapeutics, with publications, book chapters, patents (provisional) and presentations globally. Hands-on approach to engage, initiate and lead global advisory boards while navigating and mitigating business risks and optimizing drugs and trials\' probability of success. Versatile and innovative international industry physician leader accomplished in building and managing global clinical development and science departments and developing the strategic evidence-based approach, the functional structure, and the collaborative broad-based network to advance and sustain the priorities of successful life science clinical development programs, including research centers, drug development, drug safety, clinical operations, and clinical science organizations. Collaborative leadership, inspiring strategic thinking and novel clinical development ideas for new combinations and indications that address the unmet medical need. Building and nourishing relationships globally, excellent international credibility, and an extensive network of the most prominent figures and KOLs in the oncology and immuno-oncology medical community. Innovative, flexible, and novel approach to problem-solving and business excellence in a complex matrix environment to meet and exceed aggressive corporate strategic imperatives with tens of INDs, BTD, AA, ODD, 3 NDAs/BLAs and other successful submissions.

Experience

1. Global Head of Gi Oncology, Clinical Development

   Revolution Medicines

   Aug 2025 — Present

Education

• School of Medicine

  Doctor of Medicine M.D. - M.B. Ch.B., Medicine